Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05382819

A Safety, Tolerability and Preliminary Efficacy Study of FRTX-02 Capsules in Healthy Subjects and Subjects With Atopic Dermatitis

Atopic Dermatitis Eczema Clinical Trial

Official title:
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Single and Multiple Ascending Doses of FRTX-02 in Healthy Subjects and Subjects With Atopic Dermatitis

Clinical Trial Summary

FRTX-02 is an orally-available, potent and selective DYRK1A inhibitor.

Clinical Trial Description

This is a randomized, placebo controlled, double blind study in healthy subjects and subjects with atopic dermatitis that is designed to assess the safety and tolerability of FRTX-02 capsules at single and multiple ascending doses. Safety will be assessed through vital signs, ECG, adverse events and safety laboratory tests. Pharmacokinetic and pharmacodynamic information will also be collected. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05382819
Study type Interventional
Source Fresh Tracks Therapeutics, Inc.
Contact
Status Terminated
Phase Phase 1
Start date May 16, 2022
Completion date August 11, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT05579899 - Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis Phase 2
Terminated NCT04085549 - Effects of a Berry Oil Cream on Atopic Eczema and Skin N/A
Recruiting NCT05578482 - Staphylococcus Aureus and The Skin Microbiome During Flare And Resolution Of Atopic Dermatitis Phase 4
Completed NCT03540043 - Thykamine Safety and Efficacy Study in Mild-to-Moderate Atopic Dermatitis Phase 2
Recruiting NCT03293030 - Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis Phase 4
Completed NCT03386032 - 8-Week Atopic Dermatitis (AD) Treatment Study Phase 3
Completed NCT03667014 - The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients Phase 4
Completed NCT04537468 - Development of a Method to Measure mRNA Levels in Skin Samples N/A
Completed NCT03268174 - Cosmetic Study to Improve the Appearance of Skin Afflicted With Mild to Moderate Atopic Dermatitis. N/A
Active, not recruiting NCT03859986 - Study in Subjects With Moderate Atopic Dermatitis Phase 2
Completed NCT04800185 - Characterizing Skin Microbiome Change in Atopic Dermatitis Early Phase 1
Completed NCT06361992 - Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children Phase 3
Recruiting NCT06024499 - Phase 2 Trial of HY209gel in Atopic Dermatitis Patients Phase 2
Recruiting NCT03742414 - Seal, Stopping Eczema and Allergy Study Phase 2
Completed NCT03090178 - Sleep & Quality of Life Evaluation of Patients With Atopic Dermatitis Based on E-diary on a Smartphone Application and Actigraphy N/A
Recruiting NCT05935085 - This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects With Moderate to Severe Atopic Dermatitis (AD). Phase 2
Recruiting NCT03795506 - TLA in Children With Moderate to Severe Atopic Eczema (TLA4AE) N/A
Completed NCT01931644 - At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Completed NCT04773587 - Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis Phase 3
Active, not recruiting NCT04017520 - Breast Milk: Influence of the Micro-transcriptome Profile on Atopy in Children Over Time